{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:33:02Z","timestamp":1791228782406,"version":"4.1.0"},"reference-count":37,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1136\/jnnp-2014-308996","type":"journal-article","created":{"date-parts":[[2015,1,17]],"date-time":"2015-01-17T11:27:55Z","timestamp":1421494075000},"page":"879-886","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study"],"prefix":"10.1136","volume":"86","author":[{"given":"Giuseppe","family":"Lauria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Dalla Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Borghero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Caponnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Eleopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Granieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"La Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mandrioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Mazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Monsurr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimiro","family":"Pietrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Quatrale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Volanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,1,16]]},"reference":[{"key":"key-10.1136\/jnnp-2014-308996-1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1742-7843.2011.00820.x","article-title":"Organ-protective and immunomodulatory effects of erythropoietin\u2014an update on recent clinical trials","volume":"110","author":"Solling","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key-10.1136\/jnnp-2014-308996-2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"key-10.1136\/jnnp-2014-308996-3","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2014-308996-4","doi-asserted-by":"crossref","first-page":"9848","DOI":"10.1073\/pnas.0901840106","article-title":"Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons","volume":"106","author":"Sanchez","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2014-308996-5","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.051606598","article-title":"Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress","volume":"98","author":"Siren","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2014-308996-6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2119\/2006-00045.Mennini","article-title":"Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo","volume":"12","author":"Mennini","year":"2006","journal-title":"Mol Med"},{"key":"key-10.1136\/jnnp-2014-308996-7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.brainres.2004.05.040","article-title":"Enhanced expression of erythropoietin in the central nervous system of SOD1(G93A) transgenic mice","volume":"1016","author":"Chung","year":"2004","journal-title":"Brain Res"},{"key":"key-10.1136\/jnnp-2014-308996-8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.expneurol.2006.11.002","article-title":"Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model","volume":"204","author":"Grunfeld","year":"2007","journal-title":"Exp Neurol"},{"key":"key-10.1136\/jnnp-2014-308996-9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17482960600783456","article-title":"Erythropoietin does not preserve motor neurons in a mouse model of familial ALS","volume":"8","author":"Grignaschi","year":"2007","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.1136\/jnnp-2014-308996-10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neulet.2011.09.008","article-title":"Recombinant human erythropoietin reduces aggregation of mutant Cu\/Zn-binding superoxide dismutase (SOD1) in NSC-34 cells","volume":"504","author":"Cho","year":"2011","journal-title":"Neurosci Lett"},{"key":"key-10.1136\/jnnp-2014-308996-11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00702-009-0354-2","article-title":"Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis","volume":"117","author":"Janik","year":"2010","journal-title":"J Neural Transm"},{"key":"key-10.1136\/jnnp-2014-308996-12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nmd.2006.10.004","article-title":"High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia","volume":"17","author":"Just","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"key-10.1136\/jnnp-2014-308996-13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/17482960902995246","article-title":"Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability","volume":"10","author":"Lauria","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.1136\/jnnp-2014-308996-14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/01.WNL.0000148648.38313.64","article-title":"The ALSFRSr predicts survival time in an ALS clinic population","volume":"64","author":"Kaufmann","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-308996-15","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2014-308996-16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2004.10.035","article-title":"Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa","volume":"505","author":"Banks","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"key-10.1136\/jnnp-2014-308996-17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00228-005-0896-7","article-title":"The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin","volume":"61","author":"Xenocostas","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"(Pt 10)","key":"key-10.1136\/jnnp-2014-308996-18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/brain\/awm203","article-title":"Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis","volume":"130","author":"Ehrenreich","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2014-308996-19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1440-1819.2012.02359.x","article-title":"Treating patients with schizophrenia deficit with erythropoietin?","volume":"66","author":"Fond","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"key-10.1136\/jnnp-2014-308996-20","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1161\/STROKEAHA.109.549436","article-title":"The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial","volume":"40","author":"Haljan","year":"2009","journal-title":"Stroke"},{"key":"key-10.1136\/jnnp-2014-308996-21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0009-9236(98)90072-8","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects","volume":"64","author":"Cheung","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.1136\/jnnp-2014-308996-22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1073\/pnas.0307823100","article-title":"Erythropoietin both protects from and reverses experimental diabetic neuropathy","volume":"101","author":"Bianchi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.1136\/jnnp-2014-308996-23","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/WNL.0b013e318232ab9b","article-title":"ALS clinical trials: do enrolled patients accurately represent the ALS population?","volume":"77","author":"Chio","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-308996-24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.2006.104828","article-title":"Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues","volume":"79","author":"Logroscino","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2014-308996-25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000086353","article-title":"Survival of patients with amyotrophic lateral sclerosis in a population-based registry","volume":"25","author":"Millul","year":"2005","journal-title":"Neuroepidemiology"},{"key":"key-10.1136\/jnnp-2014-308996-26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/01.WNL.0000049472.47709.3B","article-title":"Prognosis in amyotrophic lateral sclerosis: a population-based study","volume":"60","author":"del Aguila","year":"2003","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-308996-27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.24096","article-title":"Long-term survival in amyotrophic lateral sclerosis: a population-based study","volume":"75","author":"Pupillo","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2014-308996-28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2014-308996-29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2014-308996-30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS","volume":"69","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2014-308996-31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/17482960902803432","article-title":"Glatiramer acetate has no impact on disease progression in ALS at 40\u2005mg\/day: a double- blind, randomized, multicentre, placebo-controlled trial","volume":"10","author":"Meininger","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.1136\/jnnp-2014-308996-32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2014-308996-33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/21678421.2013.764568","article-title":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS","volume":"14","author":"Beghi","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"key-10.1136\/jnnp-2014-308996-34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.21851","article-title":"Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study","volume":"43","author":"Chio","year":"2011","journal-title":"Muscle Nerve"},{"key":"key-10.1136\/jnnp-2014-308996-35","doi-asserted-by":"crossref","first-page":"e37885","DOI":"10.1371\/journal.pone.0037885","article-title":"A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis","volume":"7","author":"Dupuis","year":"2012","journal-title":"PLoS ONE"},{"key":"key-10.1136\/jnnp-2014-308996-36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/17482968.2010.498521","article-title":"A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis","volume":"11","author":"de Carvalho","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.1136\/jnnp-2014-308996-37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2014-308996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:56:56Z","timestamp":1601056616000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2014-308996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,16]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,7,14]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1136\/jnnp-2014-308996"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2014-308996","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,16]]}}}